Revance Therapeutics, Inc. 4/A
4/A · Revance Therapeutics, Inc. · Filed May 27, 2015
Insider Transaction Report
Form 4/AAmended
WOOTEN RONALD J
Director10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2015-05-07+8,000→ 8,000 totalExercise: $20.42Exp: 2025-05-06→ Common Stock (8,000 underlying)
Footnotes (2)
- [F1]The shares subject to the stock option shall vest on the one year anniversary of May 7, 2015, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Issuer's Non-Employee Director Compensation Policy.
- [F2]The Reporting Person is a member of the investment committee of NQ HCIF GP, Ltd. ("NovaQuest GP Ltd.") which is the general partner of NQ HCIF General Partner, L.P. ("NovaQuest GP"), which is the general partner of NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest"). Under NovaQuest's partnership agreement, the Reporting Person is deemed to hold the reported option for the benefit of NovaQuest, and must exercise the option solely upon the direction of NovaQuest, which is entitled to the shares issued upon exercise. NovaQuest, NovaQuest GP and NovaQuest GP Ltd. may be deemed indirect beneficial owners of the option, and the Reporting Person may be deemed the indirect beneficial owner of the option through his indirect interest in NovaQuest. The Reporting Person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.